Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related Searches

Medication-induced esophagitis

INTRODUCTION

Medications can induce esophageal abnormalities via both systemic and local actions. Examples of systemic effects include gastroesophageal reflux promoted by smooth muscle relaxants, and medication-induced compromise of the immune system, resulting in infectious complications. This topic review will discuss only drugs that cause direct esophageal mucosal injury.

Documentation of esophageal mucosal injury induced by the local caustic effect of medication was first described in a patient who ingested potassium chloride tablets [1]. It is likely that similar injuries had occurred prior to that time, but were underdiagnosed because of the relative lack of flexible fiberoptic endoscopy. Since the initial report, the frequency of pill-induced esophageal injury has continued to grow.

The types of medication causing direct esophageal injury can be roughly divided into antibiotics, antiinflammatory agents, and others.

  • Tetracyclines are the most common antibiotics to induce esophagitis, particularly doxycycline.
  • Essentially all of the antiinflammatory agents can damage the esophagus; the highest number of reported cases has been with aspirin.
  • The major offenders in the "other" category include potassium chloride, quinidine preparations, and iron compounds in the United States; emepronium, alprenolol, and pinaverium are common etiologies in other countries. In addition, the bisphosphonate alendronate can cause esophagitis (see 'Bisphosphonate-induced esophageal injury' below).

PATHOGENESIS

The mechanism of injury is believed to be due to prolonged contact of the caustic contents of the medication with the esophageal mucosa. This theory is supported by animal studies in which lesions identical to those found in patients were induced by direct mucosal placement of the same medications [2,3]. Clinically, this hypothesis is supported by the typical esophageal lesion showing a small punched out ulcer in a limited area that was conceivably in contact with a high concentration of medication released from a dissolving pill. In addition, the site of injury is frequently found in areas in which the esophageal lumen is compromised by the aortic arch, the esophagogastric junction, or an enlarged left atrium. Thus, medication-induced injury requires that the pill or capsule remain in the esophagus for a prolonged interval, and that its contents be inherently caustic to the esophageal mucosa.

        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Mar 2014. | This topic last updated: Dec 4, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br Heart J 1970; 32:267.
  2. Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers. a clinical and experimental study. Laryngoscope 1983; 93:184.
  3. Olovson SG, Björkman JA, Ek L, Havu N. The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model. Acta Pharmacol Toxicol (Copenh) 1983; 53:385.
  4. SCHNEYER LH, PIGMAN W, HANAHAN L, GILMORE RW. Rate of flow of human parotid, sublingual, and submaxillary secretions during sleep. J Dent Res 1956; 35:109.
  5. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65:256.
  6. Carlborg B, Densert O. Esophageal lesions caused by orally administered drugs. An experimental study in the cat. Eur Surg Res 1980; 12:270.
  7. BOLEY SJ, ALLEN AC, SCHULTZ L, SCHWARTZ S. POTASSIUM-INDUCED LESIONS OF THE SMALL BOWEL. I. CLINICAL ASPECTS. JAMA 1965; 193:997.
  8. Kikendall JW, Friedman AC, Oyewole MA, et al. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci 1983; 28:174.
  9. Henry JG, Shinner JJ, Martino JH, Cimino LE. Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride. Pediatr Cardiol 1983; 4:251.
  10. Singh NP, Rizk JG. Oesophageal perforation following ingestion of over-the-counter ibuprofen capsules. J Laryngol Otol 2008; 122:864.
  11. Wong RK, Kikendall JW, Dachman AH. Quinaglute-induced esophagitis mimicking an esophageal mass. Ann Intern Med 1986; 105:62.
  12. Bonavina L, DeMeester TR, McChesney L, et al. Drug-induced esophageal strictures. Ann Surg 1987; 206:173.
  13. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016.
  14. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437.
  15. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535.
  16. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002; 97:58.
  17. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000; 12:1.
  18. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22:15.
  19. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344.
  20. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002; 77:262.
  21. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119:631.
  22. van Staa T, Abenhaim L, Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997; 103:462.
  23. Abid S, Mumtaz K, Jafri W, et al. Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy 2005; 37:740.